EuroBiotech: More Articles of Note


> Galapagos wrapped up two moves that significantly increased its spending power. First, the biotech completed a €363.9 million ($395.2 million) financing, adding to the €973 million it had in the bank at the end of last year. Then, shareholders voted to allow Galapagos management to increase its share capital by 33% without first seeking their permission. Galapagos tried to gain such flexibility last year but was knocked back by investors. The management team’s success at the second time of asking means it now has the firepower to pull off a head-turning acquisition. Statement I De Tijd (Dutch)

> Transgene and Bristol-Myers Squibb agreed to test their drugs in combination. Bristol-Myers will provide one its checkpoint inhibitor Opdivo for use in a Transgene-sponsored trial. Transgene wants to assess the effect of the anti-PD-1 monoclonal antibody in combination with its therapeutic vaccine TG4010. The phase 2 trial will give the combination as a first-line treatment to patients with advanced non-squamous non-small cell lung cancer who have low levels of PD-L1. Release

> Kiadis Pharma filed for approval of ATIR101 in Europe. The Dutch biotech is seeking approval as an adjunctive treatment in haematopoietic stem cell transplantation for malignant disease. Kiadis made the filing after discussing data from a phase 2 trial of the adjunctive immunotherapeutic with regulators. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> ObsEva began a phase 3 program for OBE2109 in patients with uterine fibroids. The late-phase program for the gonadotropin-releasing hormone receptor antagonist consists of two phase 3 trials that will enroll 1,000 patients across 200 sites. Release

> Pfizer struck a deal with Domain Therapeutics. The agreement will see Domain use its bioSensAll technology to look at the effect of mutations on signaling pathways engaged by G protein-coupled receptors. Statement

> The European Medicines Agency added uniQure’s hemophilia B gene therapy to its PRIME scheme. PRIME status positions uniQure to receive regulatory support and fast-tracked processes as it develops AMT-060. Release

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.